The round pushed the overall funding for the Novartis-backed autoimmune and neurodegenerative disorder drug developer past $250m.

Annexon, a US-based biopharmaceutical company backed by pharmaceutical firm Novartis, completed a $100m financing round yesterday led by hedge fund manager Redmile Group. Deerfield Management, Eventide Asset Management, Farallon Capital Management, Janus Henderson Investors and Logos Capital also took part in the round as new investors, along with funds and accounts managed by BlackRock. The…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.